Tigress Initates Coverage On Eli Lilly

In a report released Friday, Tigress analyst Philip Deusen initiates coverage on Eli Lilly and Co

giving the pharmaceutical drug maker a Buy rating. Analyst at Tigress have high expectations for Eli Lilly's officience in its diabetes and cancer drug pipeline. Deusen believes the patent expirations for super drugs Cymbalta and Evista are already priced into to shares of Eli Lilly. The Tigress note displaced bullish sentiment on Eli Lilly's drugs ex-Cymbalta and Evista with sales growth of 24 percent year-over-year. If non-prescription Cialis is approved, it could be a key driver for Eli Lilly future growth.